Perrigo Company plc, received US Food and Drug Administration (FDA) approval for the generic version of Valeant Pharmaceutical International Inc's BenzaClin topical gel.
[adsense:336x280:8701650588]
Perrigo's product is therapeutically equivalent to BenzaClin gel 1%/5% and it will produce the same clinical effect and safety profile as BenzaClin gel 1%/5% when used under the conditions specified in the label.
BenzaClin topical gel (clindamycin phosphate 1% and benzoyl peroxide 5%) is indicated for the topical treatment of acne vulgaris. Combined generic and branded sales for the twelve months ending July 2015 were $231 million.
Subscribe to PharmaTutor News Alerts by Email >>
